Curcumin Intake Could Lower Serum Macrophage Migration Inhibitory Factor and Monocyte Chemoattractant Protein-1 Levels in Obese Subjects

Ismail, Nagwa Abdallah; Dayem, Soha M. Abd El; Hamed, Mona; Ayoub, Dina F.; Hassan, Elham A.; Assal, Heba Sayed

doi:10.3923/tmr.2016.82.87

Cited by 5 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study by Ismail and co‐workers, 30 obese children (aged 10–18 years) were recruited and randomly assigned to receive curcumin (500 mg daily) or placebo for 4 weeks. Curcumin supplementation reduced serum monocyte chemoattractant protein‐1 (MCP‐1) and macrophage migration inhibitory factor (MIF) levels compared with placebo (Ismail, n.d.).…”

Section: Resultsmentioning

confidence: 99%

Curcumin supplementation in pediatric patients: A systematic review of current clinical evidence

Heidari

Daei

Boozari

et al. 2021

Phytotherapy Research

View full text Add to dashboard Cite

This systematic review was designed to determine the clinical efficacy and safety of curcumin supplementation for pediatric patients based on clinical trials in children.We systematically searched electronic databases including PubMed, EMBASE, Web of Science, and Scopus for all studies that investigated curcumin administration in the pediatric population without any time frame limitation. Finally, we identified 16 studies for this review. Clinical efficacy and safety of curcumin were assessed in children with inflammatory and immune disorders (including asthma, inflammatory bowel disease (IBD), and juvenile idiopathic arthritis (JIA)), metabolic disorders, autosomal dominant polycystic kidney disease (ADPKD), cystic fibrosis (CF), tetralogy of Fallot (TOF), and infectious diseases. Curcumin was administered in a wide range of doses (45 mg-4,000 mg daily) and durations (2-48 weeks). Overall, curcumin was well tolerated in all studies and improved the severity of inflammatory and immune disorders and metabolic diseases. However, more studies are needed to clarify the role of curcumin supplementation among children with ADPKD, CF, TOF, and infectious diseases. Because of substantial heterogeneity in methodological quality, design, outcomes, dose, duration of intake, formulations, and study populations across studies, no quantitative analysis was performed. Additional large-scale, randomized, placebo-controlled clinical trials are needed to confirm the results of the conducted studies.

show abstract

Section: Resultsmentioning

confidence: 99%

Curcumin supplementation in pediatric patients: A systematic review of current clinical evidence

Heidari

Daei

Boozari

et al. 2021

Phytotherapy Research

View full text Add to dashboard Cite

show abstract

“…Further, a randomized crossover clinical trial showed that curcuminoid administration (1 g/day) with bioperine (10 mg/day) for 30 days remarkably decreased serum triglyceride levels in obese patients . Another study showed that daily administration of curcuminoids downregulated monocyte chemoattractant protein 1 and monocyte inhibitory factor in obese individuals . In addition, a randomized trial of curcuminoids (1000 mg/day) with bioperine (10 mg/day) showed a reduced serum zinc-to-copper ratio in patients with obesity .…”

Section: Clinical Trials Of Turmeric and Curcuminmentioning

confidence: 99%

“…603 Another study showed that daily administration of curcuminoids downregulated monocyte chemoattractant protein 1 and monocyte inhibitory factor in obese individuals. 614 In addition, a randomized trial of curcuminoids (1000 mg/day) with bioperine (10 mg/day) showed a reduced serum zinc-tocopper ratio in patients with obesity. 615 C-terminal cross-linking telopeptide of type I collagen (CTx), and bone mineral density (BMD).…”

Section: Turmeric and Curcumin In Inheritedmentioning

confidence: 99%

Role of Turmeric and Curcumin in Prevention and Treatment of Chronic Diseases: Lessons Learned from Clinical Trials

Kunnumakkara

Hegde

Dey

et al. 2023

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

Turmeric (Curcuma longa) has been used for thousands of years for the prevention and treatment of various chronic diseases. Curcumin is just one of >200 ingredients in turmeric. Almost 7000 scientific papers on turmeric and almost 20,000 on curcumin have been published in PubMed. Scientific reports based on cell culture or animal studies are often not reproducible in humans. Therefore, human clinical trials are the best indicators for the prevention and treatment of a disease using a given agent/drug. Herein, we conducted an extensive literature survey on PubMed and Scopus following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The keywords "turmeric and clinical trials" and "curcumin and clinical trials" were considered for data mining. A total of 148 references were found to be relevant for the key term "turmeric and clinical trials", of which 70 were common in both PubMed and Scopus, 44 were unique to PubMed, and 34 were unique to Scopus. Similarly, for the search term "curcumin and clinical trials", 440 references were found to be relevant, of which 70 were unique to PubMed, 110 were unique to Scopus, and 260 were common to both databases. These studies show that the golden spice has enormous health and medicinal benefits for humans. This Review will extract and summarize the lessons learned about turmeric and curcumin in the prevention and treatment of chronic diseases based on clinical trials.

show abstract

“…Similar disparate effects were observed in healthy adults when curcuminoids were provided in bioavailability-enhanced forms such as in solid lipid particles or as a phosphatidylcholinephytosome complex. [65][66][67] In obese individuals, findings from 10 reports [68][69][70][71][72][73][74][75][76][77] show no consistent influence of curcuminoid treatment on oxidative stress biomarkers, serum levels of cytokines, growth factors, and hormones, or on blood pressure and blood glucose and lipid concentrations, compared with controls. Dose and form of curcuminoids as well as age and gender of subjects varied considerably among trials.…”

Section: Mets and T2dmmentioning

confidence: 99%

Turmeric

2023

Nutr Today

View full text Add to dashboard Cite

Curcumin Intake Could Lower Serum Macrophage Migration Inhibitory Factor and Monocyte Chemoattractant Protein-1 Levels in Obese Subjects

Cited by 5 publications

References 17 publications

Curcumin supplementation in pediatric patients: A systematic review of current clinical evidence

Curcumin supplementation in pediatric patients: A systematic review of current clinical evidence

Role of Turmeric and Curcumin in Prevention and Treatment of Chronic Diseases: Lessons Learned from Clinical Trials

Turmeric

Contact Info

Product

Resources

About